Oropharyngeal cancers: Relationship between epidermal growth factor receptor alterations and human papillomavirus status

Abstract High-risk human papillomavirus (HR-HPV), particularly type 16, is now recognised as a causative agent in a subset of oropharyngeal squamous cell carcinomas (OPSCCs). These tumours are on the increase and generally have a better prognosis than their HPV negative counterparts. This raises the...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 2014-04, Vol.50 (6), p.1100-1111
Main Authors: Mirghani, H, Amen, F, Moreau, F, Guigay, J, Hartl, D.M, Lacau St. Guily, J
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal, Humanized - therapeutic use
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Carcinoma, Squamous Cell - drug therapy
Carcinoma, Squamous Cell - genetics
Carcinoma, Squamous Cell - virology
Cetuximab
Hematology, Oncology and Palliative Medicine
Host-Pathogen Interactions
Human papillomavirus
Human papillomavirus 16 - physiology
Humans
Medical sciences
Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
Oropharyngeal Neoplasms - drug therapy
Oropharyngeal Neoplasms - genetics
Oropharyngeal Neoplasms - virology
Papillomavirus Infections - drug therapy
Papillomavirus Infections - genetics
Papillomavirus Infections - virology
Pharmacology. Drug treatments
Prognosis
Receptor, Epidermal Growth Factor - antagonists & inhibitors
Receptor, Epidermal Growth Factor - genetics
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract High-risk human papillomavirus (HR-HPV), particularly type 16, is now recognised as a causative agent in a subset of oropharyngeal squamous cell carcinomas (OPSCCs). These tumours are on the increase and generally have a better prognosis than their HPV negative counterparts. This raises the question of de escalation therapy to reduce long term consequences in a younger cohort of patients with a long life expectancy. Several clinical trials with anti-epidermal growth factor receptor (EGFR) therapies, particularly cetuximab, are ongoing. Few data exist on the relationship between EGFR and HPV induced oropharyngeal cancers. We summarise the main studies in relation to EGFR alterations (gene copy number, protein expression and mutations) and the impact on prognosis of HPV positive tumours that express high levels of EGFR. We also discuss the opportunity of targeting this pathway in light of recent studies.
ISSN:0959-8049
1879-0852
DOI:10.1016/j.ejca.2013.12.018